

DRUG METABOLISM AND DISPOSITION

A Publication of the American Society for Pharmacology and Experimental Therapeutics

March 2021

Vol. 49, No. 3

CONTENTS

ARTICLES

- ☐ Tryptophan-75 Is a Low-Energy Channel-Gating Residue that Facilitates Substrate Egress/Access in Cytochrome P450 2D6. *Kevin D. McCarty, Samuel A. Ratliff, Kyle A. Furge, and Laura Lowe Furge* **179**
- ☐ Impact of Plasma Protein Binding in Drug Clearance Prediction: A Database Analysis of Published Studies and Implications for In Vitro-In Vivo Extrapolation. *L. J. Francis, J. B. Houston, and D. Hallifax* **188**
- ☐ Aldehyde Oxidase Contributes to All-Trans-Retinoic Acid Biosynthesis in Human Liver. *Guo Zhong, Chris J. Seaman, Erickson M. Paragas, Huaqing Xi, Karla-Luise Herpoldt, Neil P. King, Jeffrey P. Jones, and Nina Isoherranen* **202**
- ☐ Functional Characterization of 40 CYP3A4 Variants by Assessing Midazolam 1'-Hydroxylation and Testosterone 6 β -Hydroxylation. *Masaki Kumondai, Evelyn Marie Gutiérrez Rico, Eiji Hishinuma, Akiko Ueda, Sakae Saito, Daisuke Saigusa, Shu Tadaka, Kengo Kinoshita, Tomoki Nakayoshi, Akifumi Oda, Ai Abe, Masamitsu Maekawa, Nariyasu Mano, Noriyasu Hirasawa, and Masahiro Hiratsuka* **212**
- ☐ In Vivo Gene Expression Profile of Human Intestinal Epithelial Cells: From the Viewpoint of Drug Metabolism and Pharmacokinetics. *Kazuo Takayama, Kohei Ito, Akiko Matsui, Tomoki Yamashita, Kentaro Kawakami, Daisuke Hirayama, Wataru Kishimoto, Hiroshi Nakase, and Hiroyuki Mizuguchi* **221**
- ☐ Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib. *Dasean*

- T. Nardone-White, Jennifer E. Bissada, Arsany A. Abouda, and Klarissa D. Jackson* **233**
- ☐ Evaluation of Tissue Stem Cell-Derived Human Intestinal Organoids, a Physiologically Relevant Model to Evaluate Cytochrome P450 Induction in Gut. *David M. Stresser, Jun Sun, and Sarah S. Wilson* **245**
- ☐ Evaluation of the Utility of PXB Chimeric Mice for Predicting Human Liver Partitioning of Hepatic Organic Anion-Transporting Polypeptide Transporter Substrates. *Bo Feng, Rachel Pemberton, Wojciech Dworakowski, Zhengqi Ye, Craig Zetterberg, Guanyu Wang, Yoshio Morikawa, and Sanjeev Kumar* **254**
- ☐ Prediction of Transporter-Mediated Drug-Drug Interactions and Phenotyping of Hepatobiliary Transporters Involved in the Clearance of E7766, a Novel Macrocyclic-Bridged Dinucleotide. *Rongrong Jiang, Andrew Hart, Laurette Burgess, Dae-Shik Kim, Weidong George Lai, and Vaishali Dixit* **265**
- ☐ The Hypoglycemic Effect of Berberine and Berberubine Involves Modulation of Intestinal Farnesoid X Receptor Signaling Pathway and Inhibition of Hepatic Gluconeogenesis. *Runbin Sun, Bo Kong, Na Yang, Bei Cao, Dong Feng, Xiaoyi Yu, Chun Ge, Siqi Feng, Fei Fei, Jingqiu Huang, Zhenyao Lu, Yuan Xie, Chung S. Yang, Grace L. Guo, Guangji Wang, and Jiye Aa* **276**

ERRATUM

- Correction to "Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro". **287**

☐ Supplemental material is available online at <http://dmd.aspetjournals.org>.

About the cover: Channel 2b as an access/egress route for bufuralol in CYP2D6. See the article by McCarty et al. ([dx.doi.org/10.1124/dmd.120.000274](https://doi.org/10.1124/dmd.120.000274)).